CN117618433A - 赛度替尼在制备治疗和/或预防神经退行性疾病的药物、细胞保护药物中的应用 - Google Patents
赛度替尼在制备治疗和/或预防神经退行性疾病的药物、细胞保护药物中的应用 Download PDFInfo
- Publication number
- CN117618433A CN117618433A CN202311312663.2A CN202311312663A CN117618433A CN 117618433 A CN117618433 A CN 117618433A CN 202311312663 A CN202311312663 A CN 202311312663A CN 117618433 A CN117618433 A CN 117618433A
- Authority
- CN
- China
- Prior art keywords
- diseases
- disease
- ceritinib
- injury
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 78
- 229960001602 ceritinib Drugs 0.000 title claims abstract description 76
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 title claims abstract description 65
- 230000001120 cytoprotective effect Effects 0.000 title claims abstract description 19
- 230000004770 neurodegeneration Effects 0.000 title claims abstract description 16
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims description 9
- 229940079593 drug Drugs 0.000 claims abstract description 48
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 47
- 230000000694 effects Effects 0.000 claims abstract description 47
- 230000030833 cell death Effects 0.000 claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 52
- 210000004027 cell Anatomy 0.000 claims description 46
- 201000010099 disease Diseases 0.000 claims description 45
- 230000006907 apoptotic process Effects 0.000 claims description 40
- 206010021143 Hypoxia Diseases 0.000 claims description 38
- 206010028851 Necrosis Diseases 0.000 claims description 37
- 230000007954 hypoxia Effects 0.000 claims description 34
- 210000000056 organ Anatomy 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 24
- 230000006378 damage Effects 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 19
- 210000001519 tissue Anatomy 0.000 claims description 18
- 208000014674 injury Diseases 0.000 claims description 16
- 208000027418 Wounds and injury Diseases 0.000 claims description 13
- 238000001356 surgical procedure Methods 0.000 claims description 13
- 208000011580 syndromic disease Diseases 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 11
- 230000034994 death Effects 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 9
- 229940041181 antineoplastic drug Drugs 0.000 claims description 9
- 210000002216 heart Anatomy 0.000 claims description 9
- 230000017074 necrotic cell death Effects 0.000 claims description 9
- 230000001575 pathological effect Effects 0.000 claims description 9
- 230000000750 progressive effect Effects 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 230000001154 acute effect Effects 0.000 claims description 8
- 230000000740 bleeding effect Effects 0.000 claims description 8
- 208000017169 kidney disease Diseases 0.000 claims description 8
- 230000002107 myocardial effect Effects 0.000 claims description 8
- 230000002633 protecting effect Effects 0.000 claims description 8
- 238000007634 remodeling Methods 0.000 claims description 8
- 206010061216 Infarction Diseases 0.000 claims description 7
- 230000032683 aging Effects 0.000 claims description 7
- 230000004064 dysfunction Effects 0.000 claims description 7
- 230000007574 infarction Effects 0.000 claims description 7
- 210000003734 kidney Anatomy 0.000 claims description 7
- 210000004185 liver Anatomy 0.000 claims description 7
- 239000003053 toxin Substances 0.000 claims description 7
- 231100000765 toxin Toxicity 0.000 claims description 7
- 108700012359 toxins Proteins 0.000 claims description 7
- 102000014461 Ataxins Human genes 0.000 claims description 6
- 108010078286 Ataxins Proteins 0.000 claims description 6
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 6
- 208000032843 Hemorrhage Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 208000002367 Retinal Perforations Diseases 0.000 claims description 6
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims description 6
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- 230000007850 degeneration Effects 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 239000012678 infectious agent Substances 0.000 claims description 6
- 208000019423 liver disease Diseases 0.000 claims description 6
- 230000001338 necrotic effect Effects 0.000 claims description 6
- 210000005036 nerve Anatomy 0.000 claims description 6
- 238000002054 transplantation Methods 0.000 claims description 6
- 230000008733 trauma Effects 0.000 claims description 6
- 208000029578 Muscle disease Diseases 0.000 claims description 5
- 208000028389 Nerve injury Diseases 0.000 claims description 5
- 208000002193 Pain Diseases 0.000 claims description 5
- 208000034158 bleeding Diseases 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 229910052742 iron Inorganic materials 0.000 claims description 5
- 208000028867 ischemia Diseases 0.000 claims description 5
- 201000000585 muscular atrophy Diseases 0.000 claims description 5
- 230000008764 nerve damage Effects 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 4
- 208000020084 Bone disease Diseases 0.000 claims description 4
- 208000002381 Brain Hypoxia Diseases 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 208000012659 Joint disease Diseases 0.000 claims description 4
- 208000019693 Lung disease Diseases 0.000 claims description 4
- 208000021642 Muscular disease Diseases 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 208000016222 Pancreatic disease Diseases 0.000 claims description 4
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims description 4
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 4
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 4
- 208000033626 Renal failure acute Diseases 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 208000014151 Stomatognathic disease Diseases 0.000 claims description 4
- 208000007536 Thrombosis Diseases 0.000 claims description 4
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims description 4
- 201000011040 acute kidney failure Diseases 0.000 claims description 4
- 230000004900 autophagic degradation Effects 0.000 claims description 4
- 208000015100 cartilage disease Diseases 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- 210000000936 intestine Anatomy 0.000 claims description 4
- 201000006370 kidney failure Diseases 0.000 claims description 4
- 201000010901 lateral sclerosis Diseases 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 208000030159 metabolic disease Diseases 0.000 claims description 4
- 230000002438 mitochondrial effect Effects 0.000 claims description 4
- 208000005264 motor neuron disease Diseases 0.000 claims description 4
- 201000006938 muscular dystrophy Diseases 0.000 claims description 4
- 208000031225 myocardial ischemia Diseases 0.000 claims description 4
- 208000024691 pancreas disease Diseases 0.000 claims description 4
- 230000037361 pathway Effects 0.000 claims description 4
- 230000010410 reperfusion Effects 0.000 claims description 4
- 231100001229 severe poisoning Toxicity 0.000 claims description 4
- 230000000451 tissue damage Effects 0.000 claims description 4
- 231100000827 tissue damage Toxicity 0.000 claims description 4
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 108091000054 Prion Proteins 0.000 claims description 3
- 206010052428 Wound Diseases 0.000 claims description 3
- 210000004204 blood vessel Anatomy 0.000 claims description 3
- 239000013043 chemical agent Substances 0.000 claims description 3
- 210000004087 cornea Anatomy 0.000 claims description 3
- 230000003412 degenerative effect Effects 0.000 claims description 3
- 210000001508 eye Anatomy 0.000 claims description 3
- 201000006061 fatal familial insomnia Diseases 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 claims description 3
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 3
- 210000000952 spleen Anatomy 0.000 claims description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims description 2
- 206010002329 Aneurysm Diseases 0.000 claims description 2
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 2
- 208000006373 Bell palsy Diseases 0.000 claims description 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- 206010006542 Bulbar palsy Diseases 0.000 claims description 2
- 206010007556 Cardiac failure acute Diseases 0.000 claims description 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 2
- 208000006029 Cardiomegaly Diseases 0.000 claims description 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 2
- 208000002177 Cataract Diseases 0.000 claims description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims description 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 2
- 208000014311 Cushing syndrome Diseases 0.000 claims description 2
- 206010011878 Deafness Diseases 0.000 claims description 2
- 208000016192 Demyelinating disease Diseases 0.000 claims description 2
- 208000002249 Diabetes Complications Diseases 0.000 claims description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
- 206010012655 Diabetic complications Diseases 0.000 claims description 2
- 208000008960 Diabetic foot Diseases 0.000 claims description 2
- 208000003037 Diastolic Heart Failure Diseases 0.000 claims description 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 2
- 206010014561 Emphysema Diseases 0.000 claims description 2
- 206010015995 Eyelid ptosis Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 2
- 229920002527 Glycogen Polymers 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 206010018985 Haemorrhage intracranial Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims description 2
- 206010019799 Hepatitis viral Diseases 0.000 claims description 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 208000019468 Iatrogenic Disease Diseases 0.000 claims description 2
- 206010065390 Inflammatory pain Diseases 0.000 claims description 2
- 208000008574 Intracranial Hemorrhages Diseases 0.000 claims description 2
- 206010024119 Left ventricular failure Diseases 0.000 claims description 2
- 201000002832 Lewy body dementia Diseases 0.000 claims description 2
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 claims description 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 2
- 208000010428 Muscle Weakness Diseases 0.000 claims description 2
- 206010028372 Muscular weakness Diseases 0.000 claims description 2
- 208000009525 Myocarditis Diseases 0.000 claims description 2
- 201000009623 Myopathy Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000009702 Optic Disk Drusen Diseases 0.000 claims description 2
- 208000003435 Optic Neuritis Diseases 0.000 claims description 2
- 206010061323 Optic neuropathy Diseases 0.000 claims description 2
- 206010031252 Osteomyelitis Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 2
- 206010033649 Pancreatitis chronic Diseases 0.000 claims description 2
- 206010033799 Paralysis Diseases 0.000 claims description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 2
- 241000097929 Porphyria Species 0.000 claims description 2
- 208000010642 Porphyrias Diseases 0.000 claims description 2
- 208000035965 Postoperative Complications Diseases 0.000 claims description 2
- 208000028872 Progressive muscular dystrophy Diseases 0.000 claims description 2
- 206010038372 Renal arteriosclerosis Diseases 0.000 claims description 2
- 206010063897 Renal ischaemia Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 2
- 201000007737 Retinal degeneration Diseases 0.000 claims description 2
- 206010038848 Retinal detachment Diseases 0.000 claims description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 206010040070 Septic Shock Diseases 0.000 claims description 2
- 206010041591 Spinal osteoarthritis Diseases 0.000 claims description 2
- 208000006045 Spondylarthropathies Diseases 0.000 claims description 2
- 208000008253 Systolic Heart Failure Diseases 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 208000036826 VIIth nerve paralysis Diseases 0.000 claims description 2
- 206010046996 Varicose vein Diseases 0.000 claims description 2
- 208000032594 Vascular Remodeling Diseases 0.000 claims description 2
- 206010072810 Vascular wall hypertrophy Diseases 0.000 claims description 2
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims description 2
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 2
- 208000018839 Wilson disease Diseases 0.000 claims description 2
- 201000003229 acute pancreatitis Diseases 0.000 claims description 2
- 208000012998 acute renal failure Diseases 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 230000006793 arrhythmia Effects 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 208000036319 cervical spondylosis Diseases 0.000 claims description 2
- 208000007451 chronic bronchitis Diseases 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 2
- 201000002816 chronic venous insufficiency Diseases 0.000 claims description 2
- 238000007887 coronary angioplasty Methods 0.000 claims description 2
- 231100000895 deafness Toxicity 0.000 claims description 2
- 201000010064 diabetes insipidus Diseases 0.000 claims description 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 208000011325 dry age related macular degeneration Diseases 0.000 claims description 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 229940096919 glycogen Drugs 0.000 claims description 2
- 208000016354 hearing loss disease Diseases 0.000 claims description 2
- 208000018578 heart valve disease Diseases 0.000 claims description 2
- 208000014951 hematologic disease Diseases 0.000 claims description 2
- 208000031169 hemorrhagic disease Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 208000015210 hypertensive heart disease Diseases 0.000 claims description 2
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 208000023589 ischemic disease Diseases 0.000 claims description 2
- 230000000302 ischemic effect Effects 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 230000007625 mitochondrial abnormality Effects 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 208000020911 optic nerve disease Diseases 0.000 claims description 2
- 239000000162 organ preservation solution Substances 0.000 claims description 2
- 206010033103 otosclerosis Diseases 0.000 claims description 2
- 208000008510 paroxysmal tachycardia Diseases 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 108091008695 photoreceptors Proteins 0.000 claims description 2
- 208000007232 portal hypertension Diseases 0.000 claims description 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims description 2
- 201000002241 progressive bulbar palsy Diseases 0.000 claims description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 2
- 201000000196 pseudobulbar palsy Diseases 0.000 claims description 2
- 201000003004 ptosis Diseases 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 201000002793 renal fibrosis Diseases 0.000 claims description 2
- 230000004258 retinal degeneration Effects 0.000 claims description 2
- 230000004264 retinal detachment Effects 0.000 claims description 2
- 208000032253 retinal ischemia Diseases 0.000 claims description 2
- 208000004124 rheumatic heart disease Diseases 0.000 claims description 2
- 208000007442 rickets Diseases 0.000 claims description 2
- 230000036303 septic shock Effects 0.000 claims description 2
- 208000017520 skin disease Diseases 0.000 claims description 2
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 2
- 208000005801 spondylosis Diseases 0.000 claims description 2
- 230000007863 steatosis Effects 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 208000037905 systemic hypertension Diseases 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000002537 thrombolytic effect Effects 0.000 claims description 2
- 206010043778 thyroiditis Diseases 0.000 claims description 2
- 230000001256 tonic effect Effects 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- 230000001988 toxicity Effects 0.000 claims description 2
- 231100000419 toxicity Toxicity 0.000 claims description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 2
- 231100000397 ulcer Toxicity 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- 230000008728 vascular permeability Effects 0.000 claims description 2
- 201000002282 venous insufficiency Diseases 0.000 claims description 2
- 208000003663 ventricular fibrillation Diseases 0.000 claims description 2
- 201000001862 viral hepatitis Diseases 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 208000018380 Chemical injury Diseases 0.000 claims 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims 1
- 206010056328 Hepatic ischaemia Diseases 0.000 claims 1
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 102000029797 Prion Human genes 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 208000020307 Spinal disease Diseases 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 201000006815 congenital muscular dystrophy Diseases 0.000 claims 1
- 230000000893 fibroproliferative effect Effects 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 208000027185 varicose disease Diseases 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 abstract description 37
- 241000699670 Mus sp. Species 0.000 abstract description 31
- 230000003920 cognitive function Effects 0.000 abstract description 22
- 230000005779 cell damage Effects 0.000 abstract description 15
- 208000037887 cell injury Diseases 0.000 abstract description 15
- 230000013016 learning Effects 0.000 abstract description 15
- 230000015654 memory Effects 0.000 abstract description 14
- 238000002474 experimental method Methods 0.000 description 32
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 238000010175 APPswe/PSEN1dE9 Methods 0.000 description 19
- BGLPECHZZQDNCD-UHFFFAOYSA-N 4-(cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide Chemical compound C1CN(S(=O)(=O)CC)CCN1C(C=C1)=CC=C1NC1=NC=C(C(N)=O)C(NC2CC2)=N1 BGLPECHZZQDNCD-UHFFFAOYSA-N 0.000 description 13
- 101001011663 Homo sapiens Mixed lineage kinase domain-like protein Proteins 0.000 description 12
- 102100030177 Mixed lineage kinase domain-like protein Human genes 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 11
- 239000003981 vehicle Substances 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 235000002639 sodium chloride Nutrition 0.000 description 10
- 230000003833 cell viability Effects 0.000 description 9
- 230000001939 inductive effect Effects 0.000 description 9
- 230000031836 visual learning Effects 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 229950006295 cerdulatinib Drugs 0.000 description 8
- 238000012258 culturing Methods 0.000 description 8
- 210000003061 neural cell Anatomy 0.000 description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000000411 inducer Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 238000012347 Morris Water Maze Methods 0.000 description 5
- 229910002091 carbon monoxide Inorganic materials 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000007087 memory ability Effects 0.000 description 5
- 230000006886 spatial memory Effects 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 206010038897 Retinal tear Diseases 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000010255 intramuscular injection Methods 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 239000000370 acceptor Substances 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000004413 cardiac myocyte Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- -1 selenosulfonate Chemical compound 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- 102100034452 Alternative prion protein Human genes 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 101100034357 Arabidopsis thaliana RIPK gene Proteins 0.000 description 2
- 230000007082 Aβ accumulation Effects 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 2
- 102000015617 Janus Kinases Human genes 0.000 description 2
- 108010024121 Janus Kinases Proteins 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000000551 Syk Kinase Human genes 0.000 description 2
- 108010016672 Syk Kinase Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 230000007131 anti Alzheimer effect Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- IKQCSJBQLWJEPU-UHFFFAOYSA-N 2,5-dihydroxybenzenesulfonic acid Chemical compound OC1=CC=C(O)C(S(O)(=O)=O)=C1 IKQCSJBQLWJEPU-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 101150053844 APP1 gene Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101100189105 Homo sapiens PABPC4 gene Proteins 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000014060 Niemann-Pick disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000007944 Nodular Nonsuppurative Panniculitis Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 102100039424 Polyadenylate-binding protein 4 Human genes 0.000 description 1
- 208000032225 Proximal spinal muscular atrophy type 1 Diseases 0.000 description 1
- LGYDZXNSSLRFJS-IOQQVAQYSA-N SM-164 Chemical compound C1([C@H](NC(=O)[C@H]2N3C(=O)[C@@H](NC(=O)[C@H](C)NC)CCCC[C@H]3CC2)C2=CN(N=N2)CCCCC2=CC=C(C=C2)CCCCN2C=C(N=N2)[C@@H](NC(=O)[C@@H]2CC[C@@H]3CCCC[C@@H](C(N32)=O)NC(=O)[C@H](C)NC)C=2C=CC=CC=2)=CC=CC=C1 LGYDZXNSSLRFJS-IOQQVAQYSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 208000026736 Weber-Christian disease Diseases 0.000 description 1
- MIFGOLAMNLSLGH-QOKNQOGYSA-N Z-Val-Ala-Asp(OMe)-CH2F Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 MIFGOLAMNLSLGH-QOKNQOGYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000421 anti-necrotic effect Effects 0.000 description 1
- 230000002555 anti-neurodegenerative effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000006736 behavioral deficit Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 231100000060 cardiovascular toxicity Toxicity 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 231100000317 environmental toxin Toxicity 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000004434 industrial solvent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000010021 mitochondrial pathology Effects 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000021597 necroptosis Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000007512 neuronal protection Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039722 scoliosis Diseases 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及赛度替尼在制备治疗和/或预防神经退行性疾病的药物、细胞保护药物中的应用。赛度替尼显著降低神经细胞损伤和显著改善阿尔茨海默病小鼠的学习记忆能力、认知功能,减少神经细胞死亡,具有神经细胞保护作用。
Description
技术领域
本发明涉及赛度替尼在制备治疗和/或预防神经退行性疾病的药物、细胞保护药物中的应用,属于生物医药领域。本发明提供了赛度替尼的新用途和给药方式,包括抗阿尔茨海默病的作用,减轻阿尔茨海默病神经细胞损伤;以及细胞保护药物用于保护器官、组织或细胞抵抗细胞损伤和功能障碍的作用,扩大了赛度替尼的适应症范围;另外,本发明还涵盖了赛度替尼在制备细胞损伤保护药物中的应用。
背景技术
神经性退行性疾病(neurodegenerative diseases),是由神经细胞/元(细胞体、细胞核、轴突、末梢)和/或神经髓鞘随着时间的推移而逐渐丧失或者恶化,从而出现其功能障碍的疾病统称。临床上常见的神经性退行性疾病有很多,其中包括阿尔茨海默病、帕金森病、脊髓小脑共济失调等。
阿尔茨海默病(Alzheimer’s disease,AD),是一种常见以进行性认知功能障碍和行为损害为特征的中枢神经系统退行性病变,多发于老年人群,又名老年性痴呆。临床上表现为学习记忆衰退、认知功能下降、视觉空间障碍、人格及行为改变等,严重者进入完全痴呆状态。阿尔茨海默病以β-淀粉样蛋白在细胞基质沉淀聚积形成老年斑、tau蛋白过度磷酸化形成神经纤维缠结、神经元变性和丧失为主要病理特征,其神经细胞损伤变性还涉及氧化应激、炎症反应、线粒体功能障碍等机制。AD缺乏有效的治疗药物,现有的药物仅能部分缓解症状和延缓病程但无法治愈AD,且副作用明显。随着人口老龄化的加剧,AD的发病率将逐年攀升,寻求有效的治疗AD药物意义重大。
研究表明,RIPK1/RIPK3/MLKL依赖的坏死性凋亡存在于多种损伤相关性疾病中,包括缺血性脑卒中、阿尔茨海默病等神经退行性疾病,而抑制RIPK1/RIPK3/MLKL依赖的坏死性凋亡可抑制或减轻上述疾病导致的细胞死亡和组织损伤。
赛度替尼(Cerdulatinib)是一种口服的多靶点酪氨酸激酶抑制剂,可抑制脾酪氨酸激酶(SYK)和Janus激酶(JAK),显著降低一部分非霍奇金淋巴瘤(non-hodgkin’slymphoma,NHL)细胞系的细胞活性,并诱导具有BCR信号的NHL细胞系凋亡,可用于治疗外周T细胞淋巴瘤。但赛度替尼是否具有抗坏死样凋亡作用和细胞保护作用、以及抗神经退行性疾病如阿尔茨海默病作用尚未见报道。
发明内容
针对现有技术的不足,本发明的目的之一在于提供赛度替尼在制备治疗和/或预防神经退行性疾病的药物中的应用;本发明的目的之二在于提供赛度替尼在制备细胞保护药物中的应用。
为了解决上述技术问题,本发明的技术方案如下:
赛度替尼和/或其药学上可接受的盐在制备治疗和/或预防神经退行性疾病的药物中的应用。
赛度替尼的结构式如式Ⅰ所示,分子式为C20H27N7O3S:
进一步地,所述神经退行性疾病包括阿尔茨海默病、帕金森病、亨廷顿病、脊髓小脑共济失调中的一种或几种。
可选地,所述药物的活性成分包括赛度替尼或其药学上可接受的盐。
进一步地,赛度替尼作为一种化合物(药物)或其药学上可接受的盐、或共结晶体、其任何立体异构体、互变异构体、水合物、溶剂化物,而不用作抗肿瘤药物。
用赛度替尼治疗或预防阿尔茨海默病的方法,向患者施用有效量的赛度替尼。
进一步地,所述药物的给药方式包括口服给药、肌肉注射、皮下注射、静脉注射、舌下含服、病灶内或脑内或植入的递送、喷雾给药中的一种或几种,优选为肌肉、皮下或静脉注射。
进一步地,所述药物的给药方式为口服、肌肉、皮下或静脉注射给药。
进一步地,所述药物可以制备成药剂学上可以接受的任意一种剂型。
进一步地,所述剂型包括悬浮液或即用注射溶液或临时注射溶液、凝胶剂、油剂、片剂、栓剂、粉剂、胶囊剂、口服液、口含剂、颗粒剂、丸剂、散剂、膏剂、丹剂、混悬剂、乳剂、聚合物、纳米颗粒、微球、直肠用胶囊、灌肠剂、糊剂、贴剂、软膏剂、乳青剂、硬膏剂、饮剂、埋植剂、喷雾剂、气雾剂、滴剂、贴剂、滴丸剂等中的一种,可选地,通过剂型或装置进行控释和/或缓释。其中优选剂型为片剂、注射剂,如注射剂、胶囊剂、片剂、颗粒剂、散剂、喷雾剂、脂质体、口服液、滴丸中的一种。
可选地,赛度替尼为其药学上可接受的盐,所述药学上可接受的盐为药学上常用的盐,进一步地,所述盐选自乙酸盐、盐酸、氢溴酸、硝酸、硫酸、磷酸、苯甲酸盐、富马酸盐、马来酸盐、琥珀酸、酒石酸、柠檬酸盐、草酸、乙醛酸、天冬氨酸、酒石酸盐、2,5-二羟基苯甲酸盐、甲磺酸盐、乙磺酸盐、苯磺酸盐、月佳基磺酸盐、氢醌磺酸盐和对甲苯磺酸盐、或羧酸(例如甲酸、乙酸或丙酸)形成的盐中的一种或几种。
赛度替尼和/或其药学上可接受的盐在制备细胞保护药物中的应用。
进一步地,所述细胞保护药物是指具有预防、抑制和/或治疗组织、器官和/或细胞的损伤、变性和/或功能障碍的作用的药物。
进一步地,所述细胞保护药物包括用于预防、保护和/或治疗细胞抵抗病理情况或衰退过程对细胞的损伤的药物;优选地,所述病理情况或衰退过程包括病理性凋亡、病理性坏死、坏死性凋亡、细胞焦亡、铁死亡、依赖性细胞死亡、双硫死亡、自噬(抗凋亡药物和/或抗坏死药物和/或抗坏死性凋亡药物和/或抗细胞焦亡药物和/或抗铁死亡药物和/或抗依赖性细胞死亡药物和/或抗自噬药物)导致的疾病或病症中的一种或几种。
可选地,细胞保护药物包括用于脑、肺、心脏、肝、脾、血管、肠、肾、胰腺、皮肤、眼、角膜、关节等器官或细胞抵抗细胞死亡或导致细胞死亡的过程的药物,例如用于治疗坏死和/或病理性凋亡和/或坏死性凋亡和/或铁死亡和/或细胞焦亡和/或双硫死亡和/或自噬等导致的疾病的药物,或抵抗可能导致细胞死亡过程的手术操作的药物。
触发细胞死亡过程的创伤和因素可为生物来源和/或化学来源和/或物理来源。
可选地,生物来源包括:窒息、缺血/再灌注、低氧或缺氧、营养剥夺、原位产生的自由基或活性氧引起的中毒、生长因子缺乏、细胞毒素或细胞因子大量释放。还可能来源于某些事件,例如出血、意外闭塞(梗塞)和某些医疗操作(例如使用气囊充气、人工呼吸器、缝合),以及在医学治疗中用作治疗剂的生物制剂或化学制剂(例如免疫抑制剂、细胞抑制或细胞毒素剂、抗炎药)。
可选地,化学来源包括毒物引起的中毒、废弃物、pH值变化、自由基、活性氧、环境毒素。
可选地,物理来源包括撞击、割伤、暴露于辐射(X辐射、γ辐射、UV辐射、等)、体温过高、体温过低或生物体中异物或晶体的存在。
可选地,可能导致细胞死亡过程的手术操作可能为,例如,需要短暂中断血液循环导致全身或局部缺血或灌注不足(hypoperfusion)的操作(如使用止血带、止血钳等),(其发生于)例如手术期间,特别是例如对器官或心脏或主血管或外周血管进行的血管成形手术或有时需要通过(绕过)心肺系统或停止心脏的胸腔手术、心脏手术或血管手术以及需要自愿阻塞器官或部分动脉或减少通过器官的血流的任何手术期间。
可选地,可能导致细胞死亡过程的非常重要的疾病或症状包括(但不限于下列疾病或症状),这些疾病或症状中常常伴有凋亡和/或坏死和/或坏死性凋亡和/或铁死亡和/或细胞焦亡和/或双硫死亡和/或自噬存在。
进一步地,所述疾病或病症包括神经系统疾病、循环系统疾病、出血与血栓性疾病、骨骼疾病、关节疾病和软骨疾病、肢体的缺血性疾病或发作、眼科疾病、皮肤病、肾疾病、血液疾病和血管疾病、肺部疾病、胃肠道疾病、肝疾病、代谢性疾病、肌肉疾病、胰腺疾病、化学剂、传染原、毒素或药物引起的重度中毒、与衰老相关的疾病、牙齿疾病、听觉传导通路疾病、线粒体相关疾病、创伤和/或暴露于生物来源和/或化学来源和/或物理来源和/或和/或医疗操作和/或手术操作引起的病症中的一种或几种,例如意外梗塞和出血,和/或医疗操作和/或手术操作,例如细胞、组织或器官移植。
进一步地,所述神经系统疾病包括出血性脑卒中、局部缺血、颅内出血、脑出血、产前脑缺氧、成年或儿童脑缺氧、阿尔茨海默病(Alzheimer's disease)、帕金森病(Parkinson's disease)、婴儿型脊髓性肌萎缩、亨廷顿病(Huntington's disease)、帕金森叠加综合症、三叉神经痛、舌咽神经痛、肌肉疾病、贝尔麻痹、进行性延髓麻痹、脊髓性肌萎缩、原发性侧索硬化(PLS)、假性延髓麻痹、无脊椎动物盘综合征、颈椎病、遗传性肌萎缩、丛紊乱、胸廓出口破坏综合征、卟啉症、周围神经病变、多系统萎缩、皮质基底节变性、进行性核上麻痹、路易体痴呆、脱髓鞘病、额颞叶痴呆、古兰-巴雷综合征、克罗伊茨费尔特-雅各布病、进行性神经性腓骨肌萎缩症、朊粒病、致死性家族失眠症(FFI)、格-施-沙综合征(GSS)、牛海绵状脑病、癫痫、皮克氏病、AIDS痴呆综合征、不同类型脊髓小脑共济失调(SCA)、椎间盘突出症、脊柱侧弯,因暴露于工业溶剂、重金属、药物和化疗剂组成的组中的毒性化合物引起的神经损伤,因机械的、物理的或化学的创伤引起的神经系统损伤,溶酶体贮积病、尼曼-匹克病、戈谢病、疼痛中的一种或几种;优选地,所述肌肉疾病包括肌肉萎缩症,所述肌肉萎缩症包括杜兴氏肌肉萎缩症(Duchenne'smuscular dystrophy)、强直性肌肉萎缩症、肌病和肌无力、进行性肌萎缩症中的一种或几种;优选地,所述疼痛包括神经性疼痛、炎症性疼痛、糖尿病疼痛中的一种或几种;
循环系统疾病包括缺氧(anoxia)、低氧、慢性或急性心力衰竭、收缩性心力衰竭和舒张性心力衰竭、左心室功能不全、心肌梗塞后左心室功能不全、高血压心脏病、风湿性心脏病、心肌病、心肌肥厚、肥厚型心肌病、心肌炎、瓣膜性心脏病、心律失常、阵发性心动过速、心房颤动、心室纤颤、外周血管疾病、动脉瘤、慢性静脉功能不全或静脉曲张、高血压、系统性高血压、肺动脉高压、门静脉高压、由于药物(特别是抗癌药)治疗引起的心血管毒副作用中的一种或几种;
心肌重构包括心肌缺血/缺氧(如心肌梗塞)以后心肌重构、心脏手术以后心肌重构、动脉瓣(膜)疾病以后心肌重构、血管肥厚(平滑肌细胞肥大)、血管重构中的一种或几种;
出血与血栓性疾病包括血管通透性失调、溶血栓疗法后或冠状动脉血管神形成术后发生的骨骼疾病、关节疾病和软骨疾病中的一种或几种,例如骨质疏松症、骨髓炎、缺血性坏死、脊柱关节病、佝偻病、进行性骨化性纤维增殖症、库兴氏综合征(Cushing'ssyndrome)中的一种或几种;
眼科疾病包括糖尿病视网膜病变、青光眼、视网膜变性、色素性视网膜炎角膜网络状营养不良、视神经病变和视神经炎、视神经玻璃疣、上睑下垂、慢性进行性眼外肌麻痹、黄斑变性、视网膜裂孔(retinal hole)或视网膜撕裂(retinal tear)、视网膜缺血、视网膜缺血/再灌注损伤、视网膜脱离、与创伤有关的急性视网膜病变、炎性变性、手术后并发症、药物诱发性视网膜病或白内障、湿性或干性AMD相关光感受器变性中的一种或几种;
肾疾病包括肾纤维化、急性肾疾病、肾缺血、肾毛细血管梗死、急性肾损伤、急性或慢性间质性肾病、肾小球性肾炎、糖尿病性肾、肾动脉硬化、肾脏功能不全、急性或慢性肾衰竭或透析副作用、心肌缺血/再灌注以后肾衰竭中的一种或几种;
肺部疾病包括肺动脉高压、急性呼吸窘迫综合症、呼吸道感染、慢性阻塞性肺病,例如慢性支气管炎和肺气肿、囊泡性纤维化、肺囊泡病中的一种或几种;
胃肠道疾病包括溃疡或肠系膜梗塞、门脉高压中的一种或几种;
肝疾病包括自身免疫性肝炎、病毒性肝炎或其他传染原引起的肝炎、肝纤维化、酒精性肝病(ALD)、酒精性肝炎、暴发型肝炎、肝硬化、由毒素或药物引起的肝病、脂肪变性中的一种或几种,脂肪变性为肝缺血或药物伴随外源性中毒、酒精或非酒精性脂肪性肝炎(NASH);
代谢性疾病包括糖尿病、糖尿病并发症、糖尿病肾病、糖尿病视网膜病变、糖尿病足病、甲状腺炎、桥本氏甲状腺炎、葡萄糖耐受不良综合征、肥胖症、无β脂蛋白血症、高脂血症、下丘脑-垂体轴功能障碍、尿崩症、半乳糖血症、糖原病、痛风、威尔逊氏病(Wilson'sdisease)或韦伯病(Weber-Christian disease)中的一种或几种;
胰腺疾病包括慢性胰腺炎或急性胰腺炎;
化学剂、传染原、毒素或药物引起的重度中毒包括脓毒血症、败血性休克及其后果或医源性疾病;
与衰老相关疾病包括加速衰老综合症;
牙齿疾病包括导致组织损伤的疾病,例如牙周炎;
听觉传导通路疾病包括抗生素致聋和耳硬化症;
线粒体相关疾病(线粒体病理)包括先天性肌肉萎缩症伴结构性线粒体异常、弗里德利希共济失调(Friedrich's ataxia);
创伤和/或暴露于生物来源和/或化学来源和/或物理来源和/或医疗操作和/或手术操作包括意外出血、细胞、组织或器官移植。
有利地,上述药物用于预防和/或保护和/或治疗神经细胞(保护脑细胞的药物)、心肌细胞(保护心脏的药物)、肝(保护肝的药物)、肾(保护肾的药物),优选用于保护神经细胞(保护脑的药物)、心肌细胞(保护心脏的药物)、肝(保护肝的药物),更优选为神经细胞、心肌细胞。
赛度替尼和/或其药学上可接受的盐在制备离体组织和/或器官保存液中的应用。
可选地,所述离体组织和/器官包括脑、肺、心脏、肝、脾、血管、肠、肾、胰腺、皮肤、眼、角膜、关节中的一种或几种。
本发明涉及赛度替尼作为细胞保护药物,用于预防和/或保护和/或治疗移植器官和/或器官供体和/或器官受体的细胞死亡,和/或增加长期存活率,和/或限制器官的原发性功能障碍和/或限制移植器官的功能的恢复延迟和/或改善移植器官的功能恢复,主要预防或治疗移植器官的细胞死亡。
有利地,在移植之前、移植期间或移植之后,赛度替尼可用于活的或临床死亡的器官供体、组织供体、细胞供体、器官受体、组织受体、细胞受体;和/或者更具体地,器官、组织或细胞不仅是原位的器官、组织或细胞(例在医学上、外科手术中或在病理过程中),而且是离体的器官、组织或细胞(例如在某些需要暂时从体内取出器官、组织或细胞,特别是那些对其进行修饰或纯化的特定的手术中,或者在器官、组织或细胞的运输和保存期间,在移植期间或在器官、组织或细胞再植入之后它们的再灌注期间)。
因此,可以以一般的方式对个体、供体或受体或原位或离体的器官、组织或细胞进行此预防和保护,例如在某些手术期间、或在其运输期间或其保存以再植入期间。
在一个优选形式中,赛度替尼用于预防和/或保护和/或治疗:由于脑卒中(中风)或创伤引起的神经系统后遗症,由于梗塞引起的心力衰竭,在心脏、肝、肠、肺或肾移植至移植物或手术后影响它们的组织损伤,或手术程序造成的损伤。
进一步地,如上所述的药物在制备预防或治疗抗癌药物心血管毒性中的应用,所述抗癌药物包括但不限于蒽环类抗生素、酪氨酸激酶抑制剂、氟尿嘧啶类,VEGF信号通路抑制剂、免疫检查点抑制剂、铂类抗肿瘤药物、其他抗肿瘤药物。
进一步地,所述的抗癌药物包括蒽环类抗生素包括多柔比星(即阿霉素)、表柔比星(即表阿霉素)、吡柔比星、阿柔比星、伊达比星、柔红霉素、米托蒽醌等;酪氨酸激酶抑制剂,如尼诺替尼、舒尼替尼、拉帕替尼、瑞戈非尼、普纳替尼和达沙替尼;氟尿嘧啶类包括氟尿嘧啶、卡培他滨、替吉奥、替加氟;VEGF信号通路抑制剂包括贝伐珠单抗;免疫检查点抑制剂如曲妥珠单抗;铂类抗肿瘤药物顺铂等;其它抗肿瘤药物茹紫杉醇、环磷酰胺等。
除非另有说明,关于涉及赛度替尼的应用,也应考虑用于描述本发明的赛度替尼作为抗阿尔茨海默证及细胞保护药物的用途以及涉及施用和剂量的实施方式和定义。
在一个优选实施例中,赛度替尼可用作药物,用于预防和/或保护和/或治疗神经退行性疾病,如阿尔茨海默病、帕金森病、脊髓小脑共济失调中的一种或几种。
本发明人发现赛度替尼具有抗低氧/复氧和坏死样凋亡诱导剂TSZ(TNF-α、SM-164和Z-VAD-FMK)诱导的神经细胞损伤作用,抑制神经细胞坏死样凋亡,减少神经细胞死亡,可显著改善APP/PS1转基因小鼠(阿尔茨海默病小鼠模型)的学习记忆能力和认知功能,具有神经细胞保护作用,具有抗阿尔茨海默病的作用。本发明人发现赛度替尼具有神经细胞保护作用,可显著改善阿尔茨海默病小鼠的学习记忆能力、认知功能。
本发明人意外地发现,赛度替尼具有抗低氧/复氧和坏死样凋亡诱导剂TSZ诱导的神经细胞损伤作用,具有神经细胞的保护作用,可减少阿尔茨海默病神经细胞死亡,显著改善APP1/PS1转基因阿尔茨海默病小鼠的行为学功能,显著改善阿尔茨海默病小鼠的学习记忆能力、认知功能。本发明的药物具有显著的改善阿尔茨海默病的作用,有可能用于治疗阿尔茨海默病,进一步有可能用于心脏、脑等器官的保护,具有良好的开发应用前景。本发明人发现,赛度替尼具有神经细胞保护作用,可显著改善阿尔茨海默病小鼠的学习记忆能力、认知功能。
本发明扩大了赛度替尼可抵抗或治疗的适应症,可适用于细胞保护,以及抗阿尔茨海默病。
本发明涉及赛度替尼在制备治疗阿尔茨海默病药物及细胞保护药物中的应用,属于首次公开,对于可显著降低神经细胞损伤和显著改善阿尔茨海默病小鼠的学习记忆能力、认知功能,减少神经细胞死亡,具有神经细胞保护作用,是意想不到的,与赛度替尼的已知用途毫不相关,也不存在现有其他化合物给出相关启示,具备突出的实质性特点,用于治疗阿尔茨海默病及细胞保护具有显著的进步,具有良好的应用前景。本发明发现赛度替尼对神经细胞具有保护作用,可显著改善阿尔茨海默病小鼠的学习记忆能力、认知功能。
附图说明
图1为实施例1中赛度替尼对低氧/复氧和坏死样凋亡诱导剂TSZ处理的神经细胞(HT-22、SH-SY5Y)的细胞活力和LDH释放的影响情况图,A-赛度替尼对低氧/复氧处理的HT-22的细胞活力的影响情况图;B-赛度替尼对低氧/复氧处理的SH-SY5Y的细胞活力的影响情况图;C-赛度替尼对坏死样凋亡诱导剂TSZ处理的HT-22的细胞活力的影响情况图;D-赛度替尼对坏死样凋亡诱导剂TSZ处理的SH-SY5Y的细胞活力的影响情况图;E-赛度替尼对低氧/复氧处理的SH-SY5Y的LDH释放的影响情况图;F-赛度替尼对坏死样凋亡诱导剂TSZ处理的SH-SY5Y的LDH释放的影响情况图。
图2为实施例1中赛度替尼对低氧/复氧和坏死样凋亡诱导剂TSZ处理的神经细胞(SH-SY5Y)的坏死样凋亡相关分子MLKL蛋白及磷酸化的调节作用情况图,A-赛度替尼对低氧/复氧处理的神经细胞(SH-SY5Y)的坏死样凋亡相关分子MLKL蛋白及磷酸化的调节作用情况图;B-赛度替尼对低氧/复氧处理的神经细胞(SH-SY5Y)的坏死样凋亡相关分子MLKL蛋白的调节作用情况统计图;C-赛度替尼对低氧/复氧处理的神经细胞(SH-SY5Y)的坏死样凋亡相关分子MLKL磷酸化的调节作用情况统计图;D-赛度替尼对坏死样凋亡诱导剂TSZ处理的神经细胞(SH-SY5Y)的坏死样凋亡相关分子MLKL蛋白及磷酸化的调节作用情况图;E-赛度替尼对坏死样凋亡诱导剂TSZ处理的神经细胞(SH-SY5Y)的坏死样凋亡相关分子MLKL蛋白的调节作用情况统计图;F-赛度替尼对坏死样凋亡诱导剂TSZ处理的神经细胞(SH-SY5Y)的坏死样凋亡相关分子MLKL磷酸化的调节作用情况统计图。
图3为实施例2中赛度替尼对APP/PS1转基因阿尔茨海默病模型小鼠学习记忆能力、认知功能的影响情况图-新物体识别实验。
图4为实施例2中赛度替尼对APP/PS1转基因阿尔茨海默病模型小鼠学习记忆能力、认知功能的影响情况图-Y迷宫实验。
图5为实施例2中赛度替尼对APP/PS1转基因阿尔茨海默病模型小鼠空间学习记忆能力、认知功能的影响情况图-Morris水迷宫实验,A-小鼠找到原平台时间(潜伏期),B-小鼠穿越平台次数。
具体实施方式
以下将结合实施例来详细说明本发明。
赛度替尼在制备治疗阿尔茨海默病药物及细胞保护作用药物中的应用。
材料和方法:
为证明赛度替尼具有抗阿尔茨海默病和细胞保护中作用,申请人采用APP/PS1转基因阿尔茨海默病小鼠模型,并用赛度替尼每天给药处理,通过新物体识别实验、Y迷宫实验和Morris水迷宫检测神经细胞损伤及小鼠的学习记忆能力、认知功能。
为证明赛度替尼对细胞的保护作用,申请人采用低氧/复氧损伤模型、以及坏死样凋亡诱导剂TSZ(TNF-α+SM-164+Z-VAD-FMK)诱导的坏死样凋亡细胞损伤模型,并给予赛度替尼处理,通过MTS和LDH分别检测细胞活力和细胞损伤。
APP/PS1转基因雄性小鼠购自北京华阜康生物科技股份有限公司。
各实施例所用实施药品:赛度替尼(赛度替尼的化合物,其结构式如式Ⅰ所示)购于试剂公司,TSZ购于碧云天(Beyotime,江苏)。
实施例1
细胞实验:赛度替尼对低氧/复氧和坏死样凋亡诱导剂TSZ处理的HT-22和SH-SY5Y神经细胞的保护作用。
HT-22和SH-SY5Y神经细胞购于中南大学湘雅细胞库,TSZ购于碧云天(Beyotime,江苏)。
细胞培养方法:按细胞培养常规方法进行,将以上HT-22和SH-SY5Y神经细胞于DMEM高糖培养基中培养(含10%胎牛血清),细胞融合生长至80~90%时,采用胰酶消化,待细胞皱缩变圆,细胞间隙明显后,立即用培养基终止消化,将细胞打散吹匀为单个悬浮状态,分瓶传代,于37℃、含5%CO2的细胞培养箱中培养。
1.1HT-22和SH-SY5Y神经细胞低氧/复氧(Hypoxia/Reoxygenation,H/R)损伤模型的建立及药物处理
培养的HT-22或SH-SY5Y细胞融合率达80%~90%时可开始种板,用含10%胎牛血清的DMEM高糖培养基接种于培养板中,在95%空气、5% CO2、37℃的细胞培养箱中培养,待融合率达60%左右用含1%胎牛血清的DMEM高糖培基对其进行12h的同步化处理后,更换无糖DMEM在95%N2、5%CO2、37℃的细胞培养箱中培养8h,低氧结束后更换成含10%胎牛血清的DMEM高糖培养基于95%空气、5%CO2、37℃的细胞培养箱中继续培养24h。
实验分组如下:
正常对照组(Control组):常氧条件下培养36h;
低氧/复氧组(H/R组):无糖条件下低氧(1% O2)8h,复氧24h;
低氧/复氧+赛度替尼组[+Cerdulatinib组]:低氧前1h及复氧时在细胞培养基中添加5~4000nM赛度替尼(Cerdulatinib),并低氧8h,复氧24h,赛度替尼先用DMSO溶解再稀释成工作浓度;
低氧/复氧+溶媒组(DMSO):低氧/复氧时向培养基中加入与赛度替尼组等体积溶媒(DMSO)。
用MTS检测细胞活力、LDH释放率检测细胞损伤。
1.2坏死样凋亡诱导剂TSZ诱导的HT-22和SH-SY5Y神经细胞坏死样凋亡模型的建立及药物处理:
培养的HT-22或SH-SY5Y细胞融合率达80%~90%时可开始种板,用含10%胎牛血清的高糖DMEM培基接种于培养板中,在95%空气、5% CO2、37℃的细胞培养箱中培养,待融合率达60%左右,用含1%胎牛血清的高糖DMEM培基对其进行12h的同步化处理,随后更换含TSZ(稀释比为1:250)的高糖DMEM培基处理24h。
实验分组如下:
正常对照组(Control组):正常条件下培养;
TSZ组:TSZ处理24h;
TSZ+赛度替尼组[+Cerdulatinib组]:TSZ处理时在细胞培养基中添加5~10000nM的赛度替尼(Cerdulatinib);
TSZ+溶媒组(DMSO):TSZ处理时向培养基中加入与赛度替尼组等体积溶媒(DMSO)。
用MTS检测细胞活力、LDH释放率检测细胞损伤。
1.3MTS细胞活力测定
按照MTS试剂盒[Promega(Beijing)Biotech Co.,Ltd)操作说明书进行测定,根据实验要求设计分组,另设置背景空白对照组(无细胞)。待细胞融合率达80~90%,接种至96孔板中,待细胞融合率在60%左右时,开始进行后续实验,实验处理完成后以10μl/孔在96孔板中避光加入MTS,避光孵育1h左右,酶标仪测定其490nm处吸光度(控制其吸光度在0.7~1.2),其吸光度值的大小反应其细胞活力的相对大小。计算:细胞活力(%)=药物组吸光度/对照组吸光度×100%。计算各组吸光度值时,均先减去背景空白对照组吸光度值。
1.4乳酸脱氢酶(lactate dehydrogenase,LDH)释放率测定
按照乳酸脱氢酶试剂盒(碧云天,江苏)操作说明书进行测定,根据实验要求设计分组,另设置背景空白对照组(无细胞)、最大酶释放组。在样品最大酶活性孔组中加入体积为原培养基1/10的LDH释放试剂,继续培养1小时。每孔吸取120μL上清液,加入到新的96孔板中,每孔分别加入60μL LDH检测工作液,混匀,室温孵育30min(避光),在490nm测定样品吸光度。计算:细胞LDH释放率(%)=各组(包括药物处理组)吸光度/最大酶释放组吸光度×100%。计算各组吸光度值时,均先减去背景空白对照组吸光度值。
1.5Western blot(WB)检测MLKL及磷酸化MLKL(p-MLKL)表达水平
按常规方法进行,收集细胞,PBS清洗后,加入细胞压积5-7倍裂解液,冰浴裂解1h,期间每隔10min涡旋震荡一次。裂解结束后4℃,12000rpm离心15min,取上清,采用BCA法测定蛋白浓度。20-30μg蛋白样本经8% SDS-PAGE凝胶电泳分离后转膜至聚偏二氟乙烯(PVDF)膜上,封闭后,用MLKL及p-MLKL(Abcam,Cambridge,UK)抗体和β-actin(Beyotime,江苏)抗体4℃孵育过夜,洗涤后用辣根过氧化物酶(HRP)结合的相应二抗(Beyotime,江苏)孵育,经Molecular Imager ChemiDoc XRS System(Bio-Rad,Philadelphia,PA)显影,β-actin作为内参。通过Image J软件测定蛋白灰度值以检测蛋白表达水平。
1.4实验结果:
1.4.1赛度替尼具有抗低氧/复氧和坏死样凋亡诱导剂TSZ诱导的HT-22和SH-SY5Y神经细胞损伤,减少低氧/复氧和TSZ诱导的HT-22和SH-SY5Y神经细胞死亡(表现为细胞活力增加和LDH释放率降低),具有神经细胞保护作用。
图1为赛度替尼对低氧/复氧(H/R)、及TSZ处理HT-22和SH-SY5Y细胞活力和坏死(LDH释放率)的影响情况图。由图可知,赛度替尼给药后,可显著抑制低氧/复氧(图1A,B)和TSZ诱导的HT-22和SH-SY5Y神经细胞活力降低(图1C,D)以及LDH释放率增高(图1E,F),表明赛度替尼具有抗低氧/复氧和TSZ诱导的神经细胞损伤作用;数据表示为均数±标准误,n=3,**P<0.01vs Control,#P<0.05,##P<0.01vs H/R或TSZ组。
1.4.2赛度替尼具有抗低氧/复氧和TSZ诱导的SH-SY5Y神经细胞坏死样凋亡作用
如图2所示,低氧/复氧(图A,B,C)和TSZ(图D,E,F)诱导的SH-SY5Y神经细胞的坏死样凋亡相关分子MLKL及磷酸化水平p-MLKL上调,而赛度替尼可显著抑制p-MLKL上调,表明赛度替尼具有抗低氧/复氧和TSZ诱导的神经细胞坏死样凋亡作用;数据表示为均数±标准误,n=3,**P<0.01vs Control,##P<0.01vs H/R或TSZ组。
上述实施例进一步印证了赛度替尼可减少低氧/复氧和坏死样凋亡诱导剂TSZ诱导的神经细胞死亡和坏死样凋亡,具有神经细胞保护作用,可减轻神经细胞损伤,能应用于制备治疗神经细胞保护的药物。
但本发明不局限于神经细胞,其他细胞损伤及其他疾病中涉及相似的损伤机制,故该药物同样适用于治疗其他细胞损伤及相关疾病。
实施例2
动物实验:赛度替尼抗阿尔茨海默病的作用。
实验动物:APP/PS1转基因小鼠(阿尔茨海默痴呆症动物模型,鼠源背景是C57BL/6J小鼠)、雄性、5月龄、体重24~30g,和同龄C57BL/6J小鼠(雄性,5月龄,体重26~30g)购自北京华阜康生物科技有限公司。所有实验动物均饲养在温度22℃±2℃、相对湿度为45%±15%、自由饮水、遵循12小时光照/黑暗周期的SPF级饲养室内。
实验分组,将实验动物随机分为6组,每组6只,即:
正常对照组:C57BL/6J小鼠+肌肉注射溶媒
APP/PS1+溶媒组:APP/PS1小鼠+肌肉注射溶媒(即10% DMSO+30% PEG400+60%生理盐水,连续给药1个月)
APP/PS1+赛度替尼组(cerdulatinib):APP/PS1小鼠+赛度替尼(5月龄开始每天肌肉注射赛度替尼5mg/kg,连续注射1个月;其中,将赛度替尼溶于10% DMSO+30% PEG400+60%生理盐水中)。
新物体识别实验、Y迷宫和Morris水迷宫实验检测小鼠的学习记忆能力、认知功能。
检测方法及结果:
(1)赛度替尼对阿尔茨海默病模型小鼠非空间学习记忆能力、认知功能的影响—新物体识别实验。
按照新物体识别实验要求进行,实验包括三个阶段:适应期、训练期和测试期。开始新物体实验前一周每天抚摸实验鼠2~3min以减少实验鼠的紧张。采用40×40cm的旷场实验箱进行实验,实验前提前将实验鼠置于实验房内适应环境20~30min;实验鼠适应环境后开始进行新物体训练实验,旷场实验箱中放置两个在颜色、形状、材质完全一样的物体(分别记作A和B),将鼠置于其中训练10min;在训练期结束后24h后进行新物体测试实验以评估实验鼠的短时非空间学习记忆,将两个物体中的其中一个替换为另一个形状、颜色不同的物体(记作C),记录10min内实验鼠探索两个不同物体的时间。认知指数=新物体探索时间/(新物体探索时间+旧物体探索时间)×100%。
实验结果如图3所示,从图中可以得出:与正常对照组小鼠比,APP/PS1+溶媒组小鼠的认知指数显著降低,APP/PS1小鼠的非空间学习记忆能力、认知功能减弱,给予赛度替尼后(APP/PS1+赛度替尼组)的APP/PS1小鼠的认知指数显著增加(数据表示为均数±标准误,n=6,**P<0.01vs正常对照组,##P<0.01vs APP/PS1+溶媒组),结果表明,赛度替尼对阿尔茨海默病小鼠的非空间学习记忆能力、认知功能具有显著改善作用。
(2)Y迷宫实验
本实验根据参考文献1进行,检测小鼠空间学习和记忆能力。实验所用Y型迷宫由灰色有机塑料制成,由三个臂组成,相邻臂之间的角度为120°,每个臂为8cm×30cm×15cm(宽×长×高),计算机可根据迷宫正中心上方的摄像头自动追踪并记录小鼠的探索过程。随机指定三个相同的臂:(1)起始臂,小鼠开始探索(始终打开);(2)新颖臂(简称“新臂”),在第一次试验期间被阻塞,但在第二次试验期间打开,(3)其他臂(始终打开)。关闭新颖臂,将小鼠背向迷宫中心置入起始臂中,允许其在起始臂和其他臂中定向探索3min。定向探索结束后将小鼠从Y迷宫中取出,让小鼠休息2min,期间用酒精擦拭迷宫,去除小鼠气味的影响,2min结束后打开新颖臂,将小鼠背向迷宫中心置入起始臂中,允许小鼠在三个臂中自由探索1min。通过smart3.0小动物分析软件系统记录动物的运动轨迹和行为,记录小鼠在“新颖臂”(即“新臂”)停留时间,分析小鼠在新臂停留时间占总自由探索时间的百分比(即在新臂停留时间比)。
实验结果如图4所示,从图中可以得出:与正常对照组小鼠比,APP/PS1+溶媒组小鼠在“新颖臂”的停留时间显著减少,标明APP/PS1小鼠的空间学习记忆能力、认知功能减弱,给予赛度替尼后(APP/PS1+赛度替尼组)的APP/PS1小鼠在“新臂”的停留时间显著增加,在新臂停留时间比显著增加(数据表示为均数±标准误,n=6,**P<0.01vs正常对照组,##P<0.01vs APP/PS1+溶媒组),结果表明,赛度替尼对阿尔茨海默病小鼠的空间学习记忆能力、认知功能具有改善作用。
(3)赛度替尼对阿尔茨海默病模型小鼠空间学习记忆能力、认知功能的影响—Morris水迷宫实验。
按照水迷宫实验要求进行,Morris水迷宫共分为4个象限,其中一个象限中放置一个直径12cm、高35cm的平台(即目标象限),加水没过平台1~2cm,并用碳素墨水将池水染黑。定位航行实验持续5天后,撤去平台进行空间探索实验,记录小鼠到达原平台位置的时间(即潜伏期)及在目标象限停留时间(在原隐藏平台所在象限停留的时间),并分析目标象限停留时间占总探索时间的百分比。通过smart3.0小动物分析软件系统记录动物的运动轨迹和行为,分析相关数据。
实验结果如图5所示,从图中可以看出,与正常对照组小鼠比,APP/PS1+溶媒组小鼠找到原平台位置的时间(逃避潜伏期)显著增加,穿越平台次数显著减少,给予赛度替尼后(APP/PS1+赛度替尼组)的APP/PS1小鼠找到原平台的时间(逃避潜伏期)显著降低(图5A),在目标象限停留时间及停留时间比显著增加(图5B)(数据表示为均数±标准误,n=6,**P<0.01vs正常对照组,##P<0.01vs APP/PS1+溶媒组)。结果表明,赛度替尼对阿尔茨海默病小鼠的学习记忆能力、认知功能具有显著的改善作用。
以上结果表明,本发明所述赛度替尼对神经细胞具有保护作用,对阿尔茨海默病的学习记忆能力、认知功能具有显著的改善作用,可用作治疗或改善阿尔茨海默病学习记忆、认知功能药物的制备,拓宽了赛度替尼的适用症。
参考文献:
【1】Zou C,Mifflin L,Hu Z,Zhang T,Shan B,Wang H,Xing X,Zhu H,AdiconisX,Levin JZ,Li F,Liu CF,Liu JS,Yuan J.Reduction of mNAT1/hNAT2 Contributes toCerebral Endothelial Necroptosis and AβAccumulation in Alzheimer'sDisease.Cell Rep.2020;33(10):108447.
上述实施例阐明的内容应当理解为这些实施例仅用于更清楚地说明本发明,而不用于限制本发明的范围,在阅读了本发明之后,本领域技术人员对本发明的各种等价形式的修改均落入本申请所附权利要求所限定的范围。
Claims (9)
1.赛度替尼和/或其药学上可接受的盐在制备治疗和/或预防神经退行性疾病的药物中的应用。
2.根据权利要求1所述的应用,其特征在于,所述神经退行性疾病包括阿尔茨海默病、帕金森病、脊髓小脑共济失调中的一种或几种。
3.赛度替尼和/或其药学上可接受的盐在制备细胞保护药物中的应用。
4.根据权利要求3所述的应用,其特征在于,所述细胞保护药物是指具有预防、抑制和/或治疗组织、器官和/或细胞的损伤、变性和/或功能障碍的作用的药物。
5.根据权利要求4所述的应用,其特征在于,所述器官包括脑、肺、心脏、肝、脾、血管、肠、肾、胰腺、皮肤、眼、角膜、关节中的一种或几种。
6.根据权利要求3所述的应用,其特征在于,所述细胞保护药物包括用于预防、保护和/或治疗细胞抵抗病理情况或衰退过程对细胞的损伤的药物;优选地,所述病理情况或衰退过程包括病理性凋亡、坏死、坏死性凋亡、细胞焦亡、铁死亡、依赖性细胞死亡、双硫死亡、自噬所导致的疾病或病症中的一种或几种。
7.根据权利要求6所述的应用,其特征在于,所述疾病或病症包括神经系统疾病、循环系统疾病、出血与血栓性疾病、骨骼疾病、关节疾病和软骨疾病、肢体的缺血性疾病或发作、眼科疾病、皮肤病、肾疾病、血液疾病和血管疾病、肺部疾病、胃肠道疾病、肝疾病、代谢性疾病、肌肉疾病、胰腺疾病、化学剂、传染原、毒素或药物引起的重度中毒、与衰老相关的疾病、牙齿疾病、听觉传导通路疾病、线粒体相关疾病、创伤和/或暴露于生物来源和/或化学来源和/或物理来源和/或和/或医疗操作和/或手术操作引起的疾病中的一种或几种。
8.根据权利要求7所述的应用,其特征在于,所述神经系统疾病包括出血性脑卒中、局部缺血、颅内出血、脑出血、产前脑缺氧、成年或儿童脑缺氧、阿尔茨海默病、帕金森病、婴儿型脊髓性肌萎缩、亨廷顿病、帕金森叠加综合症、三叉神经痛、舌咽神经痛、肌肉疾病、贝尔麻痹、进行性延髓麻痹、脊髓性肌萎缩、原发性侧索硬化(PLS)、假性延髓麻痹、无脊椎动物盘综合征、颈椎病、遗传性肌萎缩、丛紊乱、胸廓出口破坏综合征、卟啉症、周围神经病变、多系统萎缩、皮质基底节变性、进行性核上麻痹、路易体痴呆、脱髓鞘病、额颞叶痴呆、古兰-巴雷综合征、克罗伊茨费尔特-雅各布病、进行性神经性腓骨肌萎缩症、朊粒病、致死性家族失眠症、格-施-沙综合征、牛海绵状脑病、癫痫、皮克氏病、AIDS痴呆综合征、不同类型脊髓小脑共济失调、椎间盘突出症、脊柱侧弯、由暴露于由工业溶剂、重金属、药物和化疗剂组成的组中的毒性化合物引起的神经损伤、由机械的、物理的或化学的创伤引起的神经系统损伤,溶酶体贮积病、尼曼-匹克病、戈谢病中的一种或几种;优选地,所述肌肉疾病包括肌肉萎缩症,所述肌肉萎缩症包括杜兴氏肌肉萎缩症、强直性肌肉萎缩症、肌病和肌无力、进行性肌萎缩症中的一种或几种;优选地,所述疼痛包括神经性疼痛、炎症性疼痛、糖尿病疼痛中的一种或几种;
循环系统疾病包括缺氧、低氧、慢性或急性心力衰竭、收缩性心力衰竭和舒张性心力衰竭、左心室功能不全、心肌梗塞后左心室功能不全、高血压心脏病、风湿性心脏病、心肌病、心肌肥厚、肥厚型心肌病、心肌炎、瓣膜性心脏病、心律失常、阵发性心动过速、心房颤动、心室纤颤、外周血管疾病、动脉瘤、慢性静脉功能不全或静脉曲张、高血压、系统性高血压、肺动脉高压、门静脉高压、由于药物(特别是抗癌药)治疗引起的心血管毒副作用中的一种或几种;
心肌重构包括心肌缺血/缺氧以后心肌重构、心脏手术以后心肌重构、动脉瓣(膜)疾病以后心肌重构、血管肥厚、血管重构中的一种或几种;
出血与血栓性疾病包括血管通透性失调、溶血栓疗法后或冠状动脉血管神形成术后发生的骨骼疾病、关节疾病和软骨疾病中的一种或几种,例如骨质疏松症、骨髓炎、缺血性坏死、脊柱关节病、佝偻病、进行性骨化性纤维增殖症、库兴氏综合征中的一种或几种;
眼科疾病包括糖尿病视网膜病变、青光眼、视网膜变性、色素性视网膜炎角膜网络状营养不良、视神经病变和视神经炎、视神经玻璃疣、上睑下垂、慢性进行性眼外肌麻痹、黄斑变性、视网膜裂孔或视网膜撕裂、视网膜缺血、视网膜缺血/再灌注损伤、视网膜脱离、与创伤有关的急性视网膜病变、炎性变性、手术后并发症、药物诱发性视网膜病或白内障、湿性或干性AMD相关光感受器变性中的一种或几种;
肾疾病包括肾纤维化、急性肾疾病、肾缺血、肾毛细血管梗死、急性肾损伤、急性或慢性间质性肾病、肾小球性肾炎、糖尿病性肾、肾动脉硬化、肾脏功能不全、急性或慢性肾衰竭或透析副作用、心肌缺血/再灌注以后肾衰竭中的一种或几种;
肺部疾病包括肺动脉高压、急性呼吸窘迫综合症、呼吸道感染、慢性阻塞性肺病,例如慢性支气管炎和肺气肿、囊泡性纤维化、肺囊泡病中的一种或几种;
胃肠道疾病包括溃疡或肠系膜梗塞、门脉高压中的一种或几种;
肝疾病包括自身免疫性肝炎、病毒性肝炎或其他传染原引起的肝炎、肝纤维化、酒精性肝病、酒精性肝炎、暴发型肝炎、肝硬化、由毒素或药物引起的肝病、脂肪变性中的一种或几种,脂肪变性为肝缺血或药物伴随外源性中毒、酒精或非酒精性脂肪性肝炎;
代谢性疾病包括糖尿病、糖尿病并发症、糖尿病肾病、糖尿病视网膜病变、糖尿病足病、甲状腺炎、桥本氏甲状腺炎、葡萄糖耐受不良综合征、肥胖症、无β脂蛋白血症、高脂血症、下丘脑-垂体轴功能障碍、尿崩症、半乳糖血症、糖原病、痛风、威尔逊氏病或韦伯病中的一种或几种;
胰腺疾病包括慢性胰腺炎或急性胰腺炎;
化学剂、传染原、毒素或药物引起的重度中毒包括脓毒血症、败血性休克及其后果或医源性疾病;与衰老相关疾病包括加速衰老综合症;
牙齿疾病包括导致组织损伤的疾病,例如牙周炎;
听觉传导通路疾病包括抗生素致聋和耳硬化症;
线粒体相关疾病包括先天性肌肉萎缩症伴结构性线粒体异常、弗里德利希共济失调;
创伤和/或暴露于生物来源和/或化学来源和/或物理来源和/或医疗操作和/或手术操作包括意外出血、细胞、组织或器官移植。
9.赛度替尼和/或其药学上可接受的盐在制备离体组织和/或器官保存液中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311312663.2A CN117618433A (zh) | 2023-10-11 | 2023-10-11 | 赛度替尼在制备治疗和/或预防神经退行性疾病的药物、细胞保护药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311312663.2A CN117618433A (zh) | 2023-10-11 | 2023-10-11 | 赛度替尼在制备治疗和/或预防神经退行性疾病的药物、细胞保护药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117618433A true CN117618433A (zh) | 2024-03-01 |
Family
ID=90034594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311312663.2A Pending CN117618433A (zh) | 2023-10-11 | 2023-10-11 | 赛度替尼在制备治疗和/或预防神经退行性疾病的药物、细胞保护药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117618433A (zh) |
-
2023
- 2023-10-11 CN CN202311312663.2A patent/CN117618433A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114085236A (zh) | 醛结合物和其用途 | |
IL139862A (en) | History of thiazolidine or pyroladine as effects of dipheptidyl peptides IV and pharmaceutical preparations containing them | |
KR100318168B1 (ko) | 리루졸을포함하는뉴로-aids치료를위한제약학적조성물 | |
JPH02233610A (ja) | 血管新生阻害剤 | |
WO2022194109A1 (zh) | 一种治疗视神经疾病的复合物及其制备方法和用途 | |
CN111405904A (zh) | 新型细胞保护药物 | |
EP4023227A1 (en) | Pharmaceutical composition and application thereof | |
TW201038544A (en) | Anti-neurodegenerative diseases agents | |
WO2023020488A1 (zh) | 特拉匹韦在制备治疗缺血/再灌注损伤的药物、细胞保护药物中的应用和方法 | |
EP2987786A1 (en) | Amidopyridinol derivative or pharmaceutically acceptable salt thereof and pharmaceutical composition comprising same as active component | |
ZA200309632B (en) | Medicinal composition for treatment of interstitial cystitis. | |
KR100696417B1 (ko) | 진세노사이드 Rb₁을 함유하는 뇌혈관 재생ㆍ재구축 촉진제 및 신경조직 이차변성 억제제 | |
KR20010006485A (ko) | 망막 색소상피세포의 과잉증식에 관한 질환의 예방 또는 치료제 | |
WO1998016214A1 (fr) | Inhibiteur de la cataracte secondaire | |
CN117618433A (zh) | 赛度替尼在制备治疗和/或预防神经退行性疾病的药物、细胞保护药物中的应用 | |
WO2005079792A1 (ja) | 重症糖尿病網膜症の予防又は治療剤 | |
WO2009107759A1 (ja) | 視神経障害を伴う眼疾患の予防又は治療剤 | |
EP3834828B1 (en) | Composition comprising a thiamine derivative for use in the prevention or treatment of vascular or cardiac valve calcification | |
JP2011522020A (ja) | 瘢痕を抑制する薬剤および方法 | |
JP3993647B2 (ja) | β−ナフトキノン誘導体及びそれらの塩類の新規な用途 | |
JP2001139483A (ja) | 薬用人蔘からなる脳細胞または神経細胞保護剤 | |
Maragkakis et al. | Biology of Stress Responses in Aging | |
CN113975276B (zh) | 考比替尼在制备治疗缺血/再灌注损伤药物及细胞保护药物中的应用 | |
CN117942385A (zh) | 一种细胞保护的药物组合物及应用 | |
US20230381186A1 (en) | Compounds and Methods for Treating or Preventing Anterior Segment Ocular Disorders and/or Retinal Degenerations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |